Treatment of Insomnia and Glucose Metabolism

Completed · Phase 4 · Has a placebo group

Conditions studied: Sleep, Insomnia, Insulin Resistance

In brief

Available data suggest that obtaining adequate sleep is associated with a better ability of the body to use carbohydrates as a source of energy and a lower risk of developing diabetes. The sleeping pill, Eszopiclone (Lunesta), has been approved by the Food and Drug Administration for the treatment of people who complain of trouble falling or staying asleep. This study will examine the hypothesis that the use of Eszopiclone (Lunesta) to improve the sleep of people with insomnia may also improve the use of sugar in their body.

Key facts

Study ID

NCT00724282

Run by

University of Chicago

People needed

20

Starts

2008-04-01

Expected to finish

2012-03-01

Last updated by the study team

2015-10-16

Who can join

Age: 35 and older, up to 64. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• age between 35 and 64
• must have long-standing trouble falling or staying asleep
• BMI between 22 and 34 kg/m2

You may not qualify if…

• sleep apnea or other sleep disorder other than insomnia
• diagnosis of diabetes requiring treatment with pills or insulin
• smoking
• night or shift work
• presence of a medical condition that can disrupt sleep
• women only: irregular menstrual periods or pregnancy
• use of medications/compounds that can disrupt sleep

Where it is running

• University of Chicago — Chicago, Illinois, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.